目的 比较血液透析(HD)和腹膜透析(PD)改善肾性贫血患者的疗效.方法 选择尿毒症行透析治疗患者59例,其中行腹膜透析患者24例(PD组),行血液透析患者35例(HD组).2组开始治疗时未使用促红细胞生成素,在治疗1个月时均加用促红细胞生成素,治疗2个月时均加用左旋卡尼汀联合促红细胞生成素治疗,比较2组患者透析治疗前与开始透析治疗1个月、2个月、3个月后血红蛋白(Hb)值的变化.结果 透析治疗前PD组和HD组的Hb值无明显差异(P>0.05).透析治疗前后比较,PD组和HD组治疗1个月、2个月、3个月的Hb值均明显升高(P<0.05或P< 0.01),治疗3个月>治疗2个月>治疗1个月(P<0.05或P<0.01),且透析治疗1个月、2个月、3个月后PD组的Hb值均高于HD组,差异有统计学意义(P<0.05或P<0.01).结论 无论腹膜透析和血液透析均能改善贫血,但腹膜透析疗效更明显,促红细胞生成素可有效纠正尿毒症患者的肾性贫血,并且联合左旋卡尼汀治疗效果更明显.%Objective To compare the effects of hemodialysis ( HD ) and peritoneal dialysis ( PD ) on improving renal anemia. Methods A total of 59 uremia patients were divided into two groups: PD group ( 24 patients ) and HD group ( 35 patients ). At the beginning of the therapy, the patients were not treated with erythropoietin or levocarnitine. After a month of dialysis, both of the two groups were treated with erythropoietin intravenously. Then after two months all of the patients were administered with both erythropoietin and levocarnitine. The hemoglobin ( Hb ) of the two groups was evaluated at one month,two months and three months respectively. Results There was no difference between the PD group and the HD group before dialysis. The Hb level of the two groups were increased after one month, two months and three months therapy ( P ＜ 0.05, or P ＜ 0.01 ). And the Hb level of PD group was higher than that of HD group after dialysis for one month, two months and three months ( P ＜ 0.05, or P ＜ 0.01 ). Conclusion Both PD and HD can improve anemia. And the effect of PD is more significant than that of HD. Erythropoietin can correct anemia in dialysis patients ( including PD patients and HD patients ).But the combined therapy of erythropoietin and levocarnitine is more efficient.
展开▼
